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Low molecular weight heparins (LMWHs)are the standard agents used for antithrombotic therapy and prophylaxis. Despite their
widespread use, reports about adverse eﬀects from LMWHs are very scarce. Heparin-induced skin necrosis at the injection site is a
rare adverse eﬀect, more commonlyassociatedwith unfractionated heparin (UFH) rather than with LMWH, while its mechanism
remains unclear. This paper deals with the enoxaparin induced skin necrosis.
1.Introduction
Heparin preparations are important anticoagulants and have
been successfully used for the prevention and treatment of
thromboembolic disorders for many years in most surgical
units. We report the rare occurrence of skin necrosis that
developed after enoxaparin administration. After a Medline
literature search, we have found 25 cases of skin necrosis
associated with LMWH until May 2009.
2.CaseReport
OnSeptember2007,a76-year-old malepatientwasadmitted
toourhospitalwithpainlocatedattherighthypochondrium
and epigastrium. Routine laboratory testing showed an
increased white blood cell account: 30.900 with 87.8%
neutrophils and high levels of amylase 2076. He underwent
ECHO of the abdomen which revealed cholelithiasis and
pancreatitis.
The drug history of the patient revealed the intake of
Lipitor (10mg Atorvastatin) and Co-Renitec (20mg Enal-
april + 12.5mg Hydroclorothiazide). Thrombophylaxis was
started with LMWH (Enoxaparin Sodium, 40IUs.c./24h).
The injection sites were located beside the umbilicus, in the
abdominal wall.
After 10days of LMWH administration, we observed 2
progressive, painful erythematous lesions at the injection
sites, and the next day, central necrosis of the lesions devel-
oped, with a clear line of demarcation between the aﬀected
area and surrounding tissue (the diameter of the lesion
was 20cm approximately 5cm and 3.5cm in diameter)
(Figure 1).
The histopathological examination revealed necrosis of
the surface skin as well as clots in small blood vessels with
inﬂammatory changes of the deeper skin.
Coagulation tests and platelet count were normal.
Heparin platelet factor-4 (HPF-4) antibody testing was
negative by enzyme-linked immunosorbent assay (ELISA).
The patient did not have thrombocytopenia or thrombotic
complications. He had also normal plasma concentrations
of protein C and protein S. No further platelet aggregation
studies carried out in this patient. The development of this
localized side eﬀect led to the discontinuation of treatment
with enoxaparin. We decided to switch from anticoagulant
therapy to Nadroparin until the patient discharges. Tissue
was taken for culture as well as muscle-skin biopsy, but both2 Case Reports in Medicine
Figure 1: Macroscopic appearance of the lesion.
proved to be negative. The following course was uneventful,
and the necrotic plaques disappeared within a week.
3.Discussion
Heparin-induced skin necrosis is an infrequently localized
side eﬀect that typically aﬀects middle-aged women with a
history of thrombotic disease [1]. The skin necrosis occurs
between day 5 and 11 following initiation of therapy [2]. It
mayalsooccurimmediatelyifthepatienthasbeenpreviously
sensitized or may rarely be delayed for several months after
treatment onset.
The ﬁrst symptoms are usually described as erythe-
matous, subcutaneous lesions with oedema, and pain at
the injection sites. Subsequently, bullous transformation is
observed before full-skin necrosis occurred [3]. The size of
the necrotic areas varied, but generally, the lesions appeared
to be small and circumscribed, with a maximum diameter of
a fewcentimeters. The lesionoccurredlocally atthe injection
site (abdominal wall, thigh, and arm). Less frequently,
other anatomical areas far from the injection site were also
aﬀected. These distant manifestations were apparently ran-
domindistribution.Thelesionsaremanifestedbythesudden
development of painful, erythematous, sharply demarcating
plaques progressing to purpuric plaques, which tend to be
necrotic within a short time.
The proposed mechanisms inducing heparin-induced
skin necrosis are considered: immunologically mediated
either via intravascular thrombosis resulting from heparin
induced immune aggregation of platelets (Heparin-induced
thrombocytopenia syndrome, HIT) or an Arthus-type reac-
tion due to formation of antigen-antibody complexes in
cutaneousbloodvessels(TypeIIIhypersensitivity syndrome)
or an incorrect technique of injection. Lastly, fat tissue may
have poor blood circulation, and this may result in the
heparin persisting at the injection site and causing further
damage [4].
Discontinuance of the heparin injections promptly leads
to recovery. Wound care involves cleaning and dressing the
areas of skin loss, with appropriate pain relief. Sometimes
surgery is required to remove the dead skin and a skin
g r a f tm a yb ep e r f o r m e di ft h i si se x t e n s i v e ,r e s u l t i n gi n
longer prolonged recovery time. If anticoagulation is still
required, then an alternative drug should be used, and this
may include aspirin, warfarin, hirudins, or unfractionated
heparin, depending on the cause of the heparin necrosis. If
HIT is excluded a change in heparin type may be used safely
[5].
Heparinnecrosismayrarelybefatalduetocomplications
of large areas of skin loss in severe cases or, if heparin is not
discontinued immediately and replaced by an appropriate
anticoagulant in HIT, due to clots developing internally.
The diagnosis is usually suspected clinically, but a skin
biopsymaybeperformed.Histopathologyshowsdeathofthe
surface skin and sometimes clots or inﬂammation in small
blood vessels of the deeper skin [6], as it was in our case.
4.Conclusion
Heparin-induced skin necrosis occurring after administra-
tion of a LMWH is rare, and several path mechanisms could
be involved. However, early recognition of the condition is
vital as continued treatment with heparin may precipitate
life-threatening complications in other organ systems.
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